Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Genomic characterization of host factors related to SARS-CoV-2 infection in people with dementia and control populations: The GR@ACE/DEGESCO study

  • de Rojas, Itziar
  • Frank García, Ana
  • Montes, Angel Martín
  • Bullido Gómez-Heras, María Jesús
Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Amyloid deposition in adults with drug-resistant temporal lobe epilepsy

  • Fonseca, Elena|||0000-0002-3895-1237
  • Lallana, Sofía|||0000-0002-5999-9889
  • Ortega, Gemma
  • Cano, Amanda|||0000-0001-9567-4283
  • Sarria Estrada, Silvana|||0000-0003-0083-362X
  • Pareto, Deborah|||0000-0001-7356-3769
  • Quintana, Manuel|||0000-0003-0288-9088
  • Lorenzo Bosquet, Carles|||0000-0002-8824-4602
  • López Maza, Samuel|||0000-0003-3660-2604
  • Gifreu, Ariadna
  • Campos Fernández, Daniel|||0000-0003-4795-5309
  • Abraira del Fresno, Laura|||0000-0002-5119-7929
  • Santamarina Perez, Estevo|||0000-0003-1915-0335
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Puerta, Raquel|||0000-0002-1191-5893
  • Aguilera, Núria
  • Ramis, Maribel
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Rovira, Alex|||0000-0002-2132-6750
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
  • Toledo, Manuel|||0000-0003-1550-3316
Objective: Pathological amyloid-β (Aβ) accumulation and hyperphosphorylated tau proteins have been described in resected temporal lobe specimens of epilepsy patients. We aimed to determine cerebrospinal fluid (CSF) Aβ1-42 and p181-tau levels and cerebral Aβ deposits on positron emission tomography (Aβ PET) and correlate these findings with cognitive performance in adults with drug-resistant temporal lobe epilepsy (TLE). Methods: In this cross-sectional study, we enrolled individuals with drug-resistant TLE who were 25-55 years old. Each participant underwent F-flutemetamol PET, determination of CSF Aβ1-42, p181-tau, and total tau, and a comprehensive neuropsychological assessment. We evaluated normalized standard uptake value ratios (SUVRs) for different brain regions on Aβ PET. Results: Thirty patients (mean age = 41.9 ± SD 8.1 years, 57% men) were included. The median disease duration was 9.5 (interquartile range = 4-24) years. Twenty-six patients (87%) had a clinically significant cognitive impairment on neuropsychological evaluation, 18 (69%) of the amnesic type. On Aβ PET, high uptake was observed in both mesial temporal regions (ipsilateral: SUVR z-score =.90, 95% confidence interval [CI] =.60-1.20; contralateral: SUVR z-score =.92, 95% CI =.57-1.27; p <.001), which was higher when compared to SUVR z-scores in all the remaining regions (p <.001) and in the ipsilateral anterior cingulate (SUVR z-score =.27, 95% CI =.04-.49, p =.020). No significant deposition was observed in other regions. Seven patients (23%) had low Aβ1-42 levels, and two (7%) had elevated p181-tau levels in CSF. Higher p181-tau levels correlated with poorer verbal fluency (R = -.427, p =.044). Significance: Our findings reveal a considerable Aβ deposition in mesial temporal regions and ipsilateral anterior cingulate among adults with drug-resistant TLE. Additionally, abnormal CSF Aβ1-42 levels were observed in a significant proportion of patients, and p181-tau levels were associated with verbal fluency. These results suggest that markers of neuronal damage can be observed in adults with TLE, warranting further investigation.
Repisalud
Publication Artículo científico (JournalArticle)

Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

  • de Rojas, Itziar
  • Moreno-Grau, Sonia
  • Tesi, Niccolo
  • Grenier-Boley, Benjamin
  • Andrade, Victor
  • Jansen, Iris E
  • Pedersen, Nancy L
  • Stringa, Najada
  • Zettergren, Anna
  • Hernández, Isabel
  • Montrreal, Laura
  • Antúnez, Carmen
  • Antonell, Anna
  • Tankard, Rick M
  • Bis, Joshua C
  • Sims, Rebecca
  • Bellenguez, Céline
  • Quintela, Inés
  • González-Peréz, Antonio
  • Calero, Miguel
  • Franco-Macías, Emilio
  • Macías, Juan
  • Blesa, Rafael
  • Cervera-Carles, Laura
  • Menéndez-González, Manuel
  • Frank-García, Ana
  • Royo, José Luis
  • Moreno, Fermin
  • Huerto Vilas, Raquel
  • Baquero, Miquel
  • Diez-Fairen, Mónica
  • Lage, Carmen
  • García-Madrona, Sebastián
  • García-González, Pablo
  • Alarcón-Martín, Emilio
  • Valero, Sergi
  • Sotolongo-Grau, Oscar
  • Ullgren, Abbe
  • Naj, Adam C
  • Lemstra, Afina W
  • Benaque, Alba
  • Pérez-Cordón, Alba
  • Benussi, Alberto
  • Rábano, Alberto
  • Padovani, Alessandro
  • Squassina, Alessio
  • de Mendonça, Alexandre
  • Arias Pastor, Alfonso
  • Kok, Almar A L
  • Meggy, Alun
  • Pastor, Ana Belén
  • Espinosa, Ana
  • Corma-Gómez, Anaïs
  • Martín Montes, Angel
  • Sanabria, Ángela
  • DeStefano, Anita L
  • Schneider, Anja
  • Haapasalo, Annakaisa
  • Kinhult Ståhlbom, Anne
  • Tybjærg-Hansen, Anne
  • Hartmann, Annette M
  • Spottke, Annika
  • Corbatón-Anchuelo, Arturo
  • Rongve, Arvid
  • Borroni, Barbara
  • Arosio, Beatrice
  • Nacmias, Benedetta
  • Nordestgaard, Børge G
  • Kunkle, Brian W
  • Charbonnier, Camille
  • Abdelnour, Carla
  • Masullo, Carlo
  • Martínez Rodríguez, Carmen
  • Muñoz-Fernandez, Carmen
  • Dufouil, Carole
  • Graff, Caroline
  • Ferreira, Catarina B
  • Chillotti, Caterina
  • Reynolds, Chandra A
  • Fenoglio, Chiara
  • Van Broeckhoven, Christine
  • Clark, Christopher
  • Pisanu, Claudia
  • Satizabal, Claudia L
  • Holmes, Clive
  • Buiza-Rueda, Dolores
  • Aarsland, Dag
  • Rujescu, Dan
  • Alcolea, Daniel
  • Galimberti, Daniela
  • Wallon, David
  • Seripa, Davide
  • Grünblatt, Edna
  • Dardiotis, Efthimios
  • Düzel, Emrah
  • Scarpini, Elio
  • Conti, Elisa
  • Rubino, Elisa
  • Gelpi, Ellen
  • Rodriguez-Rodriguez, Eloy
  • Duron, Emmanuelle
  • Boerwinkle, Eric
  • Ferri, Evelyn
  • Tagliavini, Fabrizio
  • Küçükali, Fahri
  • Pasquier, Florence
  • Sanchez-Garcia, Florentino
  • Mangialasche, Francesca
  • Jessen, Frank
  • Nicolas, Gaël
  • Selbæk, Geir
  • Ortega, Gemma
  • Chêne, Geneviève
  • Hadjigeorgiou, Georgios
  • Rossi, Giacomina
  • Spalletta, Gianfranco
  • Giaccone, Giorgio
  • Grande, Giulia
  • Binetti, Giuliano
  • Papenberg, Goran
  • Hampel, Harald
  • Bailly, Henri
  • Zetterberg, Henrik
  • Soininen, Hilkka
  • Karlsson, Ida K
  • Alvarez, Ignacio
  • Appollonio, Ildebrando
  • Giegling, Ina
  • Skoog, Ingmar
  • Saltvedt, Ingvild
  • Rainero, Innocenzo
  • Rosas Allende, Irene
  • Hort, Jakub
  • Diehl-Schmid, Janine
  • Van Dongen, Jasper
  • Vidal, Jean-Sébastien
  • Lehtisalo, Jenni
  • Wiltfang, Jens
  • Thomassen, Jesper Qvist
  • Kornhuber, Johannes
  • Haines, Jonathan L
  • Vogelgsang, Jonathan
  • Pineda, Juan A
  • Fortea, Juan
  • Popp, Julius
  • Deckert, Jürgen
  • Buerger, Katharina
  • Morgan, Kevin
  • Fließbach, Klaus
  • Sleegers, Kristel
  • Molina-Porcel, Laura
  • Kilander, Lena
  • Weinhold, Leonie
  • Farrer, Lindsay A
  • Wang, Li-San
  • Kleineidam, Luca
  • Farotti, Lucia
  • Parnetti, Lucilla
  • Tremolizzo, Lucio
  • Hausner, Lucrezia
  • Benussi, Luisa
  • Froelich, Lutz
  • Ikram, M Arfan
  • Deniz-Naranjo, M Candida
  • Tsolaki, Magda
  • Rosende-Roca, Maitée
  • Löwenmark, Malin
  • Hulsman, Marc
  • Spallazzi, Marco
  • Pericak-Vance, Margaret A
  • Esiri, Margaret
  • Bernal Sánchez-Arjona, María
  • Dalmasso, Maria Carolina
  • Martínez-Larrad, María Teresa
  • Arcaro, Marina
  • Nöthen, Markus M
  • Fernández-Fuertes, Marta
  • Dichgans, Martin
  • Ingelsson, Martin
  • Herrmann, Martin J
  • Scherer, Martin
  • Vyhnalek, Martin
  • Kosmidis, Mary H
  • Yannakoulia, Mary
  • Schmid, Matthias
  • Ewers, Michael
  • Heneka, Michael T
  • Wagner, Michael
  • Scamosci, Michela
  • Kivipelto, Miia
  • Hiltunen, Mikko
  • Zulaica, Miren
  • Alegret, Montserrat
  • Fornage, Myriam
  • Roberto, Natalia
  • van Schoor, Natasja M
  • Seidu, Nazib M
  • Banaj, Nerisa
  • Armstrong, Nicola J
  • Scarmeas, Nikolaos
  • Scherbaum, Norbert
  • Goldhardt, Oliver
  • Hanon, Oliver
  • Peters, Oliver
  • Skrobot, Olivia Anna
  • Quenez, Olivier
  • Lerch, Ondrej
  • Bossù, Paola
  • Caffarra, Paolo
  • Dionigi Rossi, Paolo
  • Sakka, Paraskevi
  • Hoffmann, Per
  • Holmans, Peter A
  • Fischer, Peter
  • Riederer, Peter
  • Yang, Qiong
  • Marshall, Rachel
  • Kalaria, Rajesh N
  • Mayeux, Richard
  • Vandenberghe, Rik
  • Cecchetti, Roberta
  • Ghidoni, Roberta
  • Frikke-Schmidt, Ruth
  • Sorbi, Sandro
  • Hägg, Sara
  • Engelborghs, Sebastiaan
  • Helisalmi, Seppo
  • Botne Sando, Sigrid
  • Kern, Silke
  • Archetti, Silvana
  • Boschi, Silvia
  • Fostinelli, Silvia
  • Gil, Silvia
  • Mendoza, Silvia
  • Mead, Simon
  • Ciccone, Simona
  • Djurovic, Srdjan
  • Heilmann-Heimbach, Stefanie
  • Riedel-Heller, Steffi
  • Kuulasmaa, Teemu
  • Del Ser, Teodoro
  • Lebouvier, Thibaud
  • Polak, Thomas
  • Ngandu, Tiia
  • Grimmer, Timo
  • Bessi, Valentina
  • Escott-Price, Valentina
  • Giedraitis, Vilmantas
  • Deramecourt, Vincent
  • Maier, Wolfgang
  • Jian, Xueqiu
  • Pijnenburg, Yolande A L
  • Kehoe, Patrick Gavin
  • Garcia-Ribas, Guillermo
  • Sánchez-Juan, Pascual
  • Pastor, Pau
  • Pérez-Tur, Jordi
  • Piñol-Ripoll, Gerard
  • Lopez de Munain, Adolfo
  • García-Alberca, Jose María
  • Bullido, María Jesús
  • Álvarez, Victoria
  • Lleó, Alberto
  • Real, Luis M
  • Mir, Pablo
  • Medina, Miguel
  • Scheltens, Philip
  • Holstege, Henne
  • Marquié, Marta
  • Sáez, María Eugenia
  • Carracedo, Ángel
  • Amouyel, Philippe
  • Schellenberg, Gerard D
  • Williams, Julie
  • Seshadri, Sudha
  • van Duijn, Cornelia M
  • Mather, Karen A
  • Sánchez-Valle, Raquel
  • Serrano-Ríos, Manuel
  • Orellana, Adelina
  • Tárraga, Lluís
  • Blennow, Kaj
  • Huisman, Martijn
  • Andreassen, Ole A
  • Posthuma, Danielle
  • Clarimón, Jordi
  • Boada, Mercè
  • van der Flier, Wiesje M
  • Ramirez, Alfredo
  • Lambert, Jean-Charles
  • van der Lee, Sven J
  • Ruiz, Agustín
Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer's disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer's disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer's disease.
Repisalud
Publication Artículo científico (JournalArticle)

Genomic Characterization of Host Factors Related to SARS-CoV-2 Infection in People with Dementia and Control Populations: The GR@ACE/DEGESCO Study

  • de Rojas, Itziar
  • Hernández, Isabel
  • Montrreal, Laura
  • Quintela, Inés
  • Calero, Miguel
  • Royo, José Luis
  • Huerto Vilas, Raquel
  • González-Pérez, Antonio
  • Franco-Macías, Emilio
  • Macías, Juan
  • Menéndez-González, Manuel
  • Frank-García, Ana
  • Diez-Fairen, Mónica
  • Lage, Carmen
  • García-Madrona, Sebastián
  • Aguilera, Nuria
  • García-González, Pablo
  • Puerta, Raquel
  • Sotolongo-Grau, Oscar
  • Alonso-Lana, Silvia
  • Rábano, Alberto
  • Arias Pastor, Alfonso
  • Pastor, Ana Belén
  • Corma-Gómez, Anaïs
  • Martín Montes, Angel
  • Martínez Rodríguez, Carmen
  • Buiza-Rueda, Dolores
  • Periñán, Maria Teresa
  • Rodriguez-Rodriguez, Eloy
  • Alvarez, Ignacio
  • Rosas Allende, Irene
  • Pineda, Juan A
  • Bernal Sánchez-Arjona, María
  • Fernández-Fuertes, Marta
  • Mendoza, Silvia
  • Del Ser, Teodoro
  • GR@ACE/DEGESCO Consortium
  • Garcia-Ribas, Guillermo
  • Sánchez-Juan, Pascual
  • Pastor, Pau
  • Bullido, María Jesús
  • Álvarez, Victoria
  • Real, Luis M
  • Mir, Pablo
  • Piñol-Ripoll, Gerard
  • García-Alberca, Jose María
  • Medina, Miguel
  • Orellana, Adelina
  • Butler, Chris R
  • Marquié, Marta
  • Sáez, María Eugenia
  • Carracedo, Ángel
  • Tárraga, Lluís
  • Boada, Mercè
  • Ruiz, Agustín
Emerging studies have suggested several chromosomal regions as potential host genetic factors involved in the susceptibility to SARS-CoV-2 infection and disease outcome. We nested a COVID-19 genome-wide association study using the GR@ACE/DEGESCO study, searching for susceptibility factors associated with COVID-19 disease. To this end, we compared 221 COVID-19 confirmed cases with 17,035 individuals in whom the COVID-19 disease status was unknown. Then, we performed a meta-analysis with the publicly available data from the COVID-19 Host Genetics Initiative. Because the APOE locus has been suggested as a potential modifier of COVID-19 disease, we added sensitivity analyses stratifying by dementia status or by disease severity. We confirmed the existence of the 3p21.31 region (LZTFL1, SLC6A20) implicated in the susceptibility to SARS-CoV-2 infection and TYK2 gene might be involved in COVID-19 severity. Nevertheless, no statistically significant association was observed in the COVID-19 fatal outcome or in the stratified analyses (dementia-only and non-dementia strata) for the APOE locus not supporting its involvement in SARS-CoV-2 pathobiology or COVID-19 prognosis.
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project

  • GRACE Consortium
  • DEGESCO Consortium
  • Alzheimer’s Disease Neuroimaging Initiative
  • GRACE Study Group
  • Martínez de Pancorbo Gómez, María de los Angeles
  • López de Munain Arregui, Adolfo José
Introduction: Large variability among Alzheimer's disease (AD) cases might impact genetic discoveries and complicate dissection of underlying biological pathways. Methods: Genome Research at Fundacio ACE (GR@ACE) is a genome-wide study of dementia and its clinical endophenotypes, defined based on AD's clinical certainty and vascular burden. We assessed the impact of known AD loci across endophenotypes to generate loci categories. We incorporated gene coexpression data and conducted pathway analysis per category. Finally, to evaluate the effect of heterogeneity in genetic studies, GR@ACE series were meta-analyzed with additional genome-wide association study data sets. Results: We classified known AD loci into three categories, which might reflect the disease clinical heterogeneity. Vascular processes were only detected as a causal mechanism in probable AD. The meta-analysis strategy revealed the ANKRD31-rs4704171 and NDUFAF6-rs10098778 and confirmed SCIMP-rs7225151 and CD33-rs3865444. Discussion: The regulation of vasculature is a prominent causal component of probable AD. GR@ACE meta-analysis revealed novel AD genetic signals, strongly driven by the presence of clinical heterogeneity in the AD series. (C) 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association., The authors would like to thank patients and controls who participated in this project. The Genome Research @ Fundacio ACE project (GR@ACE) is supported by Fundacion bancaria "La Caixa", Grifols SA, Fundacio ACE, and ISCIII (Ministry of Health, Spain). They also want to thank the private sponsors who support the basic and clinical projects of our institution (Piramal AG, Laboratorios Echevarne, Araclon Biotech S.A., and Fundacio ACE). They are indebted to the Trinitat Port-Carbo legacy and her family for their support of Fundacio ACE research programs. Fundacio ACE is a participating center in the Dementia Genetics Spanish Consortium (DEGESCO). A.R. and M.B. receive support from the European Union/EFPIA Innovative Medicines Initiative Joint undertaking ADAPTED and MOPEAD projects (grant numbers 115975 and 115985, respectively). M.B. and A.R. are also supported by national grants PI13/02434, PI16/01861, and PI17/01474. Accion Estrategica en Salud is integrated into the Spanish National R + D + I Plan and funded by ISCIII (Instituto de Salud Carlos III)-Subdireccion General de Evaluacion and the Fondo Europeo de Desarrollo Regional (FEDER-"Una manera de Hacer Europa"). L.M.R. is supported by Consejeria de Salud de la Junta de Andalucia (grant PI-0001/2017). Control samples and data from patients included in this study were provided in part by the National DNA Bank Carlos III (www.bancoadn.org, University of Salamanca, Spain) and Hospital Universitario Virgen de Valme (Sevilla, Spain); they were processed after standard operating procedures with the appropriate approval of the Ethical and Scientific Committee. The present work was performed as part of the Biochemistry, Molecular Biology, and Biomedicine doctoral program of S. MorenoGrau at Universitat Autonoma de Barcelona (Barcelona, Spain). Data collection and sharing for this project was partially funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). The ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering, as well as through generous contributions from the following: AbbVie; the Alzheimer's Association; the Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research provides funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study was coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for NeuroImaging at the University of Southern California. The AddNeuroMed data are from a public-private partnership supported by EFPIA companies and SMEs as part of InnoMed (Innovative Medicines in Europe), an integrated project funded by the European Union of the Sixth Framework program priority FP6-2004-LIFESCIHEALTH-5. Clinical leads responsible for data collection are Iwona K1oszewska (Lodz), Simon Lovestone (London), Patrizia Mecocci (Perugia), Hilkka Soininen (Kuopio), Magda Tsolaki (Thessaloniki), and Bruno Vellas (Toulouse). Imaging leads are Andy Simmons (London), Lars-Olad Wahlund (Stockholm), and Christian Spenger (Zurich). Bioinformatics leads are Richard Dobson (London) and Stephen Newhouse (London). Funding support for the Alzheimer's Disease Genetics Consortium (ADGC) was provided through the NIA Division of Neuroscience (U01-AG032984). The Mayo Clinic Alzheimer's Disease Genetic Studies, led by Dr. Nilufer Ertekin-Taner and Dr. Steven G. Younkin at the Mayo Clinic in Jacksonville, FL, used samples from the Mayo Clinic Study of Aging, the Mayo Clinic Alzheimer's Disease Research Center, and the Mayo Clinic Brain Bank. Data collection was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, and R01 AG003949, NINDS grant R01 NS080820, the CurePSP Foundation, and support from the Mayo Foundation. The Neocodex-Murcia study was funded by the Fundacion Alzheimur (Murcia), the Ministerio de Educacion y Ciencia (Gobierno de Espana), Corporacion Tecnologica de Andalucia, Agencia IDEA (Consejeria de Innovacion, Junta de Andalucia), the Diabetes Research Laboratory, and the Biomedical Research Foundation. University Hospital Clinico San Carlos has been supported by CIBER de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM); CIBERDEM is an ISCIII Project. The ROS/MAP study data were provided by the Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago. Data collection was supported through funding by NIA grants P30AG10161, R01AG15819, R01AG17917, R01AG30146, R01AG36836, U01AG32984 and U01AG46152, the Illinois Department of Public Health, and the Translational Genomics Research Institute. The TGEN study was supported by Kronos Life Science Laboratories, the National Institute on Aging (Arizona Alzheimer's Disease Center grants P30 AG19610 and RO1 AG023193, the Mayo Clinic Alzheimer's Disease Center grant P50 AG16574, and the Intramural Research Program), the National Alzheimer's Coordinating Center (U01 AG016976), and the state of Arizona. The authors thank the International Genomics of Alzheimer's Project (IGAP) for providing summary result data for these analyses. The investigators within IGAP contributed to the design and implementation of IGAP and/or provided data but did not participate in analysis or writing of this report. IGAP was made possible by the generous participation of the control subjects, the patients, and their families. The i-Select chip was funded by the French National Foundation on Alzheimer's disease and related disorders. European Alzheimer's Disease Initiative (EADI) was supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Universite de Lille 2, and the Lille University Hospital. GERAD was supported by the Medical Research Council (grant no. 503480), Alzheimer's Research UK (grant no. 503176), the Wellcome Trust (grant no. 082604/2/07/Z), and German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) grant no. 01GI0102, 01GI0711, 01GI0420. CHARGE was partly supported by the NIH/NIA grant R01 AG033193 and the NIA AG081220 and AGES contract N01-AG12100, the NHLBI grant R01 HL105756, the Icelandic Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was supported by the NIH/NIA grants: U01 AG032984, U24 AG021886, U01 AG016976, and the Alzheimer's Association grant ADGC-10-196728.
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Common Variants in Alzheimer’s Disease and Risk Stratification by Polygenic Risk Scores

  • De Rojas, Itziar
  • EADB contributors
  • The GR@ACE study group
  • DEGESCO Consortium
  • IGAP (ADGC, CHARGE, EADI, GERAD)
  • PGC-ALZ consortia
  • López de Munain Arregui, Adolfo José
Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n=409,435 and validation size n=58,190). Here, we add six variants associated with Alzheimer's disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer's disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer's disease., The present work has been performed as part of the doctoral program of I. de Rojas at the Universitat de Barcelona (Barcelona, Spain) supported by national grant from the Instituto de Salud Carlos III FI20/00215. The Genome Research @ Fundació ACE project (GR@ACE) is supported by Grifols SA, Fundación bancaria “La Caixa”, Fundació ACE, and CIBERNED. A.R. and M.B. receive support from the European Union/EFPIA Innovative Medicines Initiative Joint undertaking ADAPTED and MOPEAD projects (grant numbers 115975 and 115985, respectively). M.B. and A.R. are also supported by national grants PI13/02434, PI16/01861, PI17/01474, PI19/01240 and PI19/01301. Acción Estratégica en Salud is integrated into the Spanish National R + D + I Plan and funded by ISCIII (Instituto de Salud Carlos III)—Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de hacer Europa”). The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. Genotyping of the Dutch case-control samples was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW project number 733051061). 100-Plus study. This work was supported by Stichting Alzheimer Nederland (WE09.2014-03), Stichting Diorapthe, horstingstuit foundation, Memorabel (ZonMW project number 733050814, 733050512) and Stichting VUmc Fonds. Genotyping of the 100-Plus Study was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW project numb 733051061). Longitudinal Aging Study Amsterdam (LASA) is largely supported by a grant from the Netherlands Ministry of Health, Welfare and Sports, Directorate of LongTerm Care. This work was supported by a grant (European Alzheimer DNA BioBank, EADB) from the EU Joint Program—Neurodegenerative Disease Research (JPND) and also funded by Inserm, Institut Pasteur de Lille, the Lille Métropole Communauté Urbaine, the French government’s LABEX DISTALZ program (development of innovative strategies for a transdisciplinary approach to AD). Genotyping of the German case-control samples was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND (German Federal Ministry of Education and Research, BMBF: 01ED1619A). The i–Select chips was funded by the French National Foundation on AD and related disorders. EADI was supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Université de Lille 2 and the Lille University Hospital. GERAD was supported by the Medical Research Council (Grant n° 503480), Alzheimer’s Research UK (Grant n° 503176), the Wellcome Trust (Grant n° 082604/2/07/Z) and German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) grant n° 01GI0102, 01GI0711, 01GI0420. CHARGE was partly supported by the NIA/NHLBI grants AG049505, AG058589, HL105756 and AGES contract N01–AG–12100, the Icelandic Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was supported by the NIH/NIA grants: U01 AG032984, U24 AG021886, U01 AG016976, and the Alzheimer’s Association grant ADGC–10–196728
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

  • de Rojas, Itziar
  • Frank García, Ana
  • Bullido Gómez-Heras, María Jesús
Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project.

  • Moreno-Grau, Sonia
  • de Rojas, Itziar
  • Hernández Alvarez, María Isabel
  • Quintela, Inés
  • Montrreal, Laura
  • Alegret, Montserrat
  • Hernández-Olasagarre, Begoña
  • Madrid, Laura
  • González-Perez, Antonio
  • Maroñas, Olalla
  • Rosende-Roca, Maitée
  • Mauleón, Ana
  • Vargas, Liliana
  • Lafuente, Asunción
  • Abdelnour, Carla
  • Rodríguez-Gómez, Octavio
  • Gil, Silvia
  • Santos-Santos, Miguel Ángel
  • Espinosa Cardiel, Ana
  • Ortega, Gemma
  • Sanabria, Ángela
  • Pérez-Cordón, Alba
  • Cañabate, Pilar
  • Moreno, Mariola
  • Preckler, Silvia
  • Ruiz, Susana
  • Aguilera, Nuria
  • Pineda, Juan Antonio
  • Macías, Juan
  • Alarcón-Martín, Emilio
  • Sotolongo-Grau, Oscar
  • GR@ACE consortium
  • DEGESCO consortium
  • Alzheimer&apos;s Disease Neuroimaging Initiative
  • Marquié, Marta
  • Monté Rubio, Gemma C.
  • Valero, Sergi
  • Benaque, Alba
  • Clarimón, Jordi
  • Bullido, María Jesús
  • García-Ribas, Guillermo
  • Pastor, Pau
  • Sánchez-Juan, Pascual
  • Álvarez, Victoria
  • Piñol-Ripoll, Gerard
  • García-Alberca, Jose Maria
  • Royo, José Luis
  • Franco, Emilio
  • Mir, Pablo
  • Calero, Miguel
  • Medina, Miguel
  • Rábano, Alberto
  • Ávila, Jesús
  • Antúnez, Carmen
  • Real, Luis Miguel
  • Orellana, Adelina
  • Carracedo Álvarez, Ángel
  • Saéz, Maria Eugenia
  • Tárraga, Lluís
  • Boada, Mercè
  • Ruiz, Agustín
Introduction: Large variability among Alzheimer's disease (AD) cases might impact genetic discoveries and complicate dissection of underlying biological pathways. Methods: Genome Research at Fundacio ACE (GR@ACE) is a genome-wide study of dementia and its clinical endophenotypes, defined based on AD's clinical certainty and vascular burden. We assessed the impact of known AD loci across endophenotypes to generate loci categories. We incorporated gene coexpression data and conducted pathway analysis per category. Finally, to evaluate the effect of heterogeneity in genetic studies, GR@ACE series were meta-analyzed with additional genome-wide association study data sets. Results: We classified known AD loci into three categories, which might reflect the disease clinical heterogeneity. Vascular processes were only detected as a causal mechanism in probable AD. The meta-analysis strategy revealed the ANKRD31-rs4704171 and NDUFAF6-rs10098778 and confirmed SCIMP-rs7225151 and CD33-rs3865444. Discussion: The regulation of vasculature is a prominent causal component of probable AD. GR@ACE meta-analysis revealed novel AD genetic signals, strongly driven by the presence of clinical heterogeneity in the AD series.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

  • Rojas, Itziar de
  • Moreno-Grau, Sonia
  • Tesi, Niccolo
  • Grenier-Boley, Benjamin
  • Andrade, Victor
  • Jansen, Iris E.
  • Pedersen, N. L.
  • Stringa, N.
  • Zettergren, Anna
  • Hernández, Isabel
  • Montrreal, Laura
  • Rossi, Giacomina
  • Tankard, R. M.
  • Wiltfang, J.
  • Giegling, Ina
  • Seidu, N. M.
  • Dalmasso, Maria Carolina
  • Benussi, A.
  • Boschi, Silvia
  • Sáez, María Eugenia
  • Binetti, Giuliano
  • Royo, José Luis
  • Pérez-Tur, Jordi
  • Spalletta, Gianfranco
  • Corbaton-Anchuelo, A.
  • Froelich, L.
  • Satizabal, Claudia L.
  • Hagg, S.
  • Ortega, G.
  • Peters, Oliver
  • Vogelgsang, Jonathan
  • Serrano-Ríos, M.
  • Gil, S.
  • Djurovic, Srdjan
  • Van Dongen, Jasper
  • Deramecourt, V.
  • Kalaria, R. N.
  • Wang, L. S.
  • Goldhardt, O.
  • Charbonnier, Camille
  • Farotti, Lucia
  • Kornhuber, Johannes
  • Andreassen, Ole A.
  • Álvarez, Victoria
  • Herrmann, Martin J.
  • Pasquier, Florence
  • Calero, Miguel
  • Holmes, Clive
  • Haapasalo, Annakaisa
  • Scherbaum, Norbert
  • Scheltens, Philip
  • Caffarra, P.
  • Pineda, Juan A.
  • Del Ser, Teodoro
  • Hort, Jakub
  • Espinosa, A.
  • Bullido, María Jesús
  • Hampel, Harald
  • Medina, Miguel
  • Williams, Julie
  • Sims, Rebecca
  • Martinez-Larrad, M. T.
  • Riederer, Peter
  • Esiri, M.
  • Botne Sando, S.
  • Grunblatt, E.
  • Hoffmann, Per
  • Hiltunen, Mikko
  • Kern, Silke
  • Mendoza, Silvia
  • Kilander, Lena
  • Jessen, F.
  • Ghidoni, R.
  • Giedraitis, Vilmantas
  • Molina-Porcel, Laura
  • Sánchez-Juan, Pascual
  • Schmid, Matthias
  • van Duijn, Cornelia M.
  • Antonell, A.
  • Mir, Pablo
  • Moreno, F.
  • Ferreira, Catarina B.
  • Skrobot, Olivia
  • Sánchez-Valle, Raquel
  • Chene, G.
  • Duron, Emmanuelle
  • Martín Montes, Ángel
  • Ciccone, Simona
  • Piñol-Ripoll, Gerard
  • Ngandu, Tiia
  • Dardiotis, Efthimios
  • Scherer, Martin
  • Arosio, Beatrice
  • Meggy, A.
  • Sotolongo-Grau, Oscar
  • Selbaek, Geir
  • Aarsland, Dag
  • Seshadri, Sudha
  • Bailly, Henri
  • Sánchez-García, Florentino
  • Roberto, Natalia
  • Armstrong, Nicola J.
  • Farrer, Lindsay A.
  • Popp, Julius
  • Riedel-Heller, Steffi
  • Fernández-Fuertes, Marta
  • Scamosci, Michela
  • Alcolea, Daniel
  • Rosas Allende, Irene
  • Marquié, Marta
  • Benussi, Luisa
  • Ewers, Michael
  • Antúnez, Carmen
  • van Broeckhoven, Christine
  • Masullo, C.
  • Vyhnalek, Martin
  • Bossu, Paola
  • Appollonio, I.
  • Mayeux, R.
  • Lerch, Ondrej
  • Rábano, Alberto
  • Quenez, Olivier
  • Schneider, Anja
  • Wallon, David
  • Macías Sánchez, Juan
  • PGC-ALZ consortia
  • Yang, Q.
  • Helisalmi, Seppo
  • Huisman, M.
  • Lambert, Jean-Charles
  • Kehoe, Patrick G.
  • Heneka, Michael T.
  • DEGESCO consortium
  • Papenberg, Goran
  • Lowenmark, M.
  • Frikke-Schmidt, Ruth
  • Fornage, Myriam
  • Kunkle, Brian W.
  • Heilmann-Heimbach, Stefanie
  • Posthuma, Danielle
  • Tremolizzo, Lucio
  • Amouyel, Philippe
  • Franco-Macías, Emilio
  • Munoz-Fernandez, C.
  • Sorbi, Sandro
  • Küçükali, Fahri
  • Dionigi Rossi, P.
  • Huerto Vilas, Raquel
  • Spallazzi, Marco
  • Alarcón-Martín, Emilio
  • Maier, Wolfgang
  • de Mendonça, Alexandre
  • The GR@ACE study group
  • Benaque, Alba
  • EADB contributors
  • IGAP (ADGC, CHARGE, EADI, GERAD)
  • van der Lee, Sven J.
  • DeStefano, Anita
  • Lleó, Alberto
  • Kosmidis, Mary H.
  • Rongve, A.
  • Nicolas, Gael
  • Escott-Price, Valentina
  • Tybjaerg-Hansen, Anne
  • Chillotti, Caterina
  • Pastor, Pau
  • Buiza-Rueda, Dolores
  • Alegret, Montserrat
  • Lage, Carmen
  • Holmans, Peter A.
  • Polak, Thomas
  • Pastor, Ana Belén
  • Nöthen, Markus M.
  • García-Ribas, Guillermo
  • Pijnenburg, Yolande A L
  • Vidal, Jean-Sebastien
  • Squassina, Alessio
  • Kuulasmaa, Teemu
  • Pericak-Vance, M. A.
  • Pisanu, Claudia
  • Fliessbach, Klaus
  • Grimmer, Timo
  • Galimberti, Daniela
  • Parnetti, L.
  • López de Munain, Adolfo
  • Soininen, Hilkka
  • Carracedo, Ángel
  • Deckert, Jurgen
  • Karlsson, I. K.
  • Buerger, Katharina
  • Clark, Christopher
  • Cecchetti, Roberta
  • Fostinelli, Silvia
  • Deniz-Naranjo, M. C.
  • Engelborghs, S.
  • Álvarez, Ignacio
  • Sakka, Paraskevi
  • Thomassen, Jesper Qvist
  • Ramirez, A.
  • Holstege, Henne
  • Marshall, Rachel
  • Haines, Jonathan L.
  • Hulsman, Marc
  • Kleineidam, Luca
  • Ferri, E.
  • Pérez-Cordón, Alba
  • Menéndez-González, Manuel
  • van der Flier, Wiesje M.
  • Rainero, Innocenzo
  • Rujescu, D.
  • Wagner, Michael
  • Corma-Gómez, Anaïs
  • Lebouvier, T.
  • Ruiz, Agustín
  • Vandenberghe, Rik
  • Weinhold, Leonie
  • Padovani, Alessandro
  • Diehl-Schmid, Janine
  • Mead, Simon
  • Fenoglio, Chiara
  • Conti, Elisa
  • Díez-Fairen, Mónica
  • Fischer, Peter
  • Abdelnour, Carla
  • Giaccone, G.
  • González-Pérez, Antonio
  • Hartmann, Annette M.
  • Hadjigeorgiou, Georgios
  • Zulaica, M.
  • Sleegers, Kristel
  • Martínez Rodríguez, Carmen
  • García-González, Pablo
  • Rubino, Elisa
  • Bis, Joshua C.
  • Orellana, Adelina
  • Zetterberg, Henrik
  • Schellenberg, Gerard D.
  • Borroni, Barbara
  • Sanabria, Angela
  • Fortea, J.
  • Reynolds, C. A.
  • Gelpí, Ellen
  • Bernal Sánchez-Arjona, María
  • Boerwinkle, Eric
  • Mather, K. A.
  • Jian, X.
  • Saltvedt, Ingvild
  • Frank-García, Ana
  • Rosende-Roca, Maitee
  • Kinhult Stahlbom, Anne
  • Hanon, Olivier
  • Skoog, Ingmar
  • Kivipelto, Miia
  • Lehtisalo, Jenni
  • García-Alberca, José María
  • Dufouil, Carole
  • Bellenguez, Celine
  • Ingelsson, Martin
  • Nacmias, B.
  • Spottke, Annika
  • Ullgren, Abbe
  • Hausner, Lucrezia
  • Arias Pastor, Alfonso
  • Tsolaki, Magda
  • Seripa, Davide
  • Naj, A. C.
  • Clarimón, Jordi
  • Nordestgaard, Borge G.
  • Valero, Sergi
  • van Schoor, N. M.
  • Scarpini, E.
  • Graff, Caroline
  • Boada, Mercè
  • Tagliavini, Fabrizio
  • Scarmeas, N.
  • García-Madrona, Sebastián
  • Yannakoulia, Mary
  • Banaj, Nerisa
  • Blennow, Kaj
  • Duzel, Emrah
  • Tárraga, Lluís
  • Lemstra, A. W.
  • Morgan, K.
  • Kok, A. A. L.
  • Bessi, Valentina
  • Baquero, Miquel
  • Rodríguez-Rodríguez, Eloy
  • Cervera-Carles, Laura
  • Archetti, Silvana
  • Grande, Giulia
  • Dichgans, Martin
  • Arcaro, Marina
  • Blesa, Rafael
  • Real, Luis Miguel
  • Ikram, M. Arfan
  • Mangialasche, Francesca
  • Quintela, Inés
16 páginas, 5 figuras, Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer's disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer's disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer's disease., The present work has been performed as part of the doctoral program of I. de Rojas at the Universitat de Barcelona (Barcelona, Spain) supported by national grant from the Instituto de Salud Carlos III FI20/00215. The Genome Research @ Fundació ACE project (GR@ACE) is supported by Grifols SA, Fundación bancaria “La Caixa”, Fundació ACE, and CIBERNED. A.R. and M.B. receive support from the European Union/EFPIA Innovative Medicines Initiative Joint undertaking ADAPTED and MOPEAD projects (grant numbers 115975 and 115985, respectively). M.B. and A.R. are also supported by national grants PI13/02434, PI16/01861, PI17/01474, PI19/01240 and PI19/01301. Acción Estratégica en Salud is integrated into the Spanish National R + D + I Plan and funded by ISCIII (Instituto de Salud Carlos III)—Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de hacer Europa”). Some control samples and data from patients included in this study were provided in part by the National DNA Bank Carlos III (www.bancoadn.org, University of Salamanca, Spain) and Hospital Universitario Virgen de Valme (Sevilla, Spain); they were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committee. Amsterdam dementia Cohort (ADC): Research of the Alzheimer center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. Genotyping of the Dutch case-control samples was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW project number 733051061). 100-Plus study: We are grateful for the collaborative efforts of all participating centenarians and their family members and/or relations. This work was supported by Stichting Alzheimer Nederland (WE09.2014-03), Stichting Diorapthe, horstingstuit foundation, Memorabel (ZonMW project number 733050814, 733050512) and Stichting VUmc Fonds. Genotyping of the 100-Plus Study was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW project number 733051061). Longitudinal Aging Study Amsterdam (LASA) is largely supported by a grant from the Netherlands Ministry of Health, Welfare and Sports, Directorate of Long-Term Care. The authors are grateful to all LASA participants, the fieldwork team and all researchers for their ongoing commitment to the study. This work was supported by a grant (European Alzheimer DNA BioBank, EADB) from the EU Joint Program—Neurodegenerative Disease Research (JPND) and also funded by Inserm, Institut Pasteur de Lille, the Lille Métropole Communauté Urbaine, the French government’s LABEX DISTALZ program (development of innovative strategies for a transdisciplinary approach to AD). Genotyping of the German case-control samples was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND (German Federal Ministry of Education and Research, BMBF: 01ED1619A). Full acknowledgments for the studies that contributed data can be found in the Supplementary Note. We thank the numerous participants, researchers, and staff from many studies who collected and contributed to the data. We thank the International Genomics of Alzheimer’s Project (IGAP) for providing summary results data for these analyses. The investigators within IGAP contributed to the design and implementation of IGAP and/or provided data but did not participate in analysis or writing of this report. IGAP was made possible by the generous participation of the control subjects, the patients, and their families. The i–Select chips was funded by the French National Foundation on AD and related disorders. EADI was supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Université de Lille 2 and the Lille University Hospital. GERAD was supported by the Medical Research Council (Grant n° 503480), Alzheimer’s Research UK (Grant n° 503176), the Wellcome Trust (Grant n° 082604/2/07/Z) and German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) grant n° 01GI0102, 01GI0711, 01GI0420. CHARGE was partly supported by the NIA/NHLBI grants AG049505, AG058589, HL105756 and AGES contract N01–AG–12100, the Icelandic Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was supported by the NIH/NIA grants: U01 AG032984, U24 AG021886, U01 AG016976, and the Alzheimer’s Association grant ADGC–10–196728. This research has been conducted using the UK Biobank public resource obtained through the University of Edinburg Data Share (https://datashare.is.ed.ac.uk/handle/10283/3364)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Correlations between the NMR Lipoprotein Profile, APOE Genotype, and Cholesterol Efflux Capacity of Fasting Plasma from Cognitively Healthy Elderly Adults

  • Rojas, Itziar de
  • Barrio, Laura
  • Hernández, Isabel
  • Montrreal, Laura
  • García-González, Pablo
  • Marquié, Marta
  • Valero, Sergi
  • Cano, Amanda
  • Orellana, Adelina
  • Boada, Mercè
  • Mañes, Santos
  • Ruiz, Agustín
Cholesterol efflux capacity (CEC) is of interest given its potential relationship with several important clinical conditions including Alzheimer's disease. The inactivation of the APOE locus in mouse models supports the idea that it is involved in determining the CEC. With that in mind, we examine the impact of the plasma metabolome profile and the APOE genotype on the CEC in cognitively healthy elderly subjects. The study subjects were 144 unrelated healthy individuals. The plasma CEC was determined by exposing cultured mouse macrophages treated with BODIPY-cholesterol to human plasma. The metabolome profile was determined using NMR techniques. Multiple regression was performed to identify the most important predictors of CEC, as well as the NMR features most strongly associated with the APOE genotype. Plasma 3-hydroxybutyrate was the variable most strongly correlated with the CEC (r = 0.365; p = 7.3 × 10-6). Male sex was associated with a stronger CEC (r = -0.326, p = 6.8 × 10-5). Most of the NMR particles associated with the CEC did not correlate with the APOE genotype. The NMR metabolomics results confirmed the APOE genotype to have a huge effect on the concentration of plasma lipoprotein particles as well as those of other molecules including omega-3 fatty acids. In conclusion, the CEC of human plasma was associated with ketone body concentration, sex, and (to a lesser extent) the other features of the plasma lipoprotein profile. The APOE genotype exerted only a weak effect on the CEC via the modulation of the lipoprotein profile. The APOE locus was associated with omega-3 fatty acid levels independent of the plasma cholesterol level., A.R. and S.M. are funded by the Innovative Medicines Initiative 2 Joint Undertaking, which receives support from the European Union Horizon 2020 Research And Innovation Programme (ADAPTED grant no. 115975). S.M.’s research is also funded by the Spanish Ministry of Science and Innovation (PID2020-116303RB-I00/MCIN/AEI/10.13039/501100011033). A.R.’s research is also supported by Instituto de Salud Carlos III (ISCIII) via grants PI13/02434, PI16/01861, PI19/01301, and PI22/01403 Acción Estratégica en Salud, within the framework of the Spanish National R+D+I Plan and funded by the ISCIII-Subdirección General de Evaluación and the European Regional Development Fund (EDRF), as well as by the JPco-fuND-2 “Multinational Research Projects on Personalized Medicine for Neurodegenerative Diseases” PREADAPT project. I.d.R. is supported by a national grant from the Instituto de Salud Carlos III (ISCIII) FI20/00215. M.M. receives support from Instituto de Salud Carlos III (ISCIII) via grant PI19/00335 Acción Estratégica en Salud, within the framework of the Spanish National R+D+I Plan and funded by ISCIII-Subdirección General de Evaluación and the EDRF. AC acknowledges the support of the Instituto de Salud Carlos III (ISCIII) grant Sara Borrell (CD22/00125) and Ministerio de Ciencia e Innovación, Proyectos de Generación de Conocimiento grant PID2021-122473OA-I00. Fundacio ACE researchers research receives support from Grifols, Roche, Janssen, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de Análisis Echevarne, and IrsiCaixa., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Intermediate and Expanded HTT Alleles and the Risk for α-Synucleinopathies

  • Pérez-Oliveira, Sergio
  • Álvarez, Ignacio
  • Rosas Allende, Irene
  • Menéndez-González, Manuel
  • Blázquez-Estrada, Marta
  • Aguilar Barberá, Miquel
  • Corte, Daniela
  • Buongiorno, Maria Teresa
  • Molina-Porcel, Laura
  • Aldecoa, Iban
  • Martí, María-José
  • Sánchez-Juan, Pascual
  • Infante, Jon
  • González-Aramburu, Isabel
  • García-González, Pablo
  • Rosende-Roca, Maitee
  • Boada, Mercè
  • Ruiz, Agustín
  • Periñán, María Teresa
  • Macías García, Daniel
  • Muñoz-Delgado, Laura
  • Gómez-Garre, Pilar
  • Mir, Pablo
  • Clarimón, Jordi
  • Lleó, Alberto
  • Alcolea, Daniel
  • Casa-Fages, Beatriz de la
  • Duarte, Israel
  • Álvarez, Victoria
  • Pastor, Pau
[Background] Previous studies suggest a link between CAG repeat number in the HTT gene and non-Huntington neurodegenerative diseases., [Objective] The aim is to analyze whether expanded HTT CAG alleles and/or their size are associated with the risk for developing α-synucleinopathies or their behavior as modulators of the phenotype., [Methods] We genotyped the HTT gene CAG repeat number and APOE-Ɛ isoforms in a case-control series including patients with either clinical or neuropathological diagnosis of α-synucleinopathy., [Results] We identified three Parkinson's disease (PD) patients (0.30%) and two healthy controls (0.19%) carrying low-penetrance HTT repeat expansions whereas none of the dementia with Lewy bodies (DLB) or multisystem atrophy (MSA) patients carried pathogenic HTT expansions. In addition, a clear increase in the number of HTT CAG repeats was found among DLB and PD groups influenced by the male gender and also by the APOE4 allele among DLB patients. HTT intermediate alleles' (IAs) distribution frequency increased in the MSA group compared with controls (8.8% vs. 3.9%, respectively). These differences were indeed statistically significant in the MSA group with neuropathological confirmation. Two MSA HTT CAG IAs carriers with 32 HTT CAG repeats showed isolated polyQ inclusions in pons and basal nuclei, which are two critical structures in the neurodegeneration of MSA., [Conclusions] Our results point to a link between HTT CAG number, HTT IAs, and expanded HTT CAG repeats with other non-HD brain pathology and support the hypothesis that they can share common neurodegenerative pathways., This work is supported by the Fondo de Investigaciones Sanitarias' Spanish government ICIII FIS-FEDER grants (ID grants: PI21/0467 to V.A., and PI21/00886 to P.P.). Sergio Pérez-Oliveira is supported by Fundación Parkinson Asturias-Obra Social Cajastur. M.T.P. was supported by the Spanish Ministry of Education, Culture and Sports [FPU16/05061]. D.M.-G. was supported by the “Río Hortega” program [CM18/00142] from the Instituto de Salud Carlos III (ISCIII-FEDER). P.G.-G. was supported by the “Nicolás Monardes” program [C-0048-2017] from the Andalusian Regional Ministry of Health. The Genome Research @ Fundació ACE project (GR@ACE) is supported by Grifols SA, Fundación bancaria “La Caixa,” Fundació ACE, and CIBERNED. P.G. is supported by CIBERNED employment plan CNV-304-PRF-866. A.R. and M.B. receive support from the European Union/EFPIA Innovative Medicines Initiative Joint undertaking ADAPTED and MOPEAD projects (grant numbers 115975 and 115985, respectively). M.B. and A.R. are also supported by National Grants (PI13/02434, PI16/01861, PI17/01474, PI19/01240, and PI19/01301). Acción Estratégica en Salud is integrated into the Spanish National R + D + I Plan and funded by ISCIII (Instituto de Salud Carlos III)—Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de hacer Europa”)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project.

  • Moreno-Grau, Sonia
  • de Rojas, Itziar
  • Hernández Alvarez, María Isabel
  • Quintela, Inés
  • Montrreal, Laura
  • Alegret, Montserrat
  • Hernández-Olasagarre, Begoña
  • Madrid, Laura
  • González-Perez, Antonio
  • Maroñas, Olalla
  • Rosende-Roca, Maitée
  • Mauleón, Ana
  • Vargas, Liliana
  • Lafuente, Asunción
  • Abdelnour, Carla
  • Rodríguez-Gómez, Octavio
  • Gil, Silvia
  • Santos-Santos, Miguel Ángel
  • Espinosa Cardiel, Ana
  • Ortega, Gemma
  • Sanabria, Ángela
  • Pérez-Cordón, Alba
  • Cañabate, Pilar
  • Moreno, Mariola
  • Preckler, Silvia
  • Ruiz, Susana
  • Aguilera, Nuria
  • Pineda, Juan Antonio
  • Macías, Juan
  • Alarcón-Martín, Emilio
  • Sotolongo-Grau, Oscar
  • GR@ACE consortium
  • DEGESCO consortium
  • Alzheimer's Disease Neuroimaging Initiative
  • Marquié, Marta
  • Monté Rubio, Gemma C.
  • Valero, Sergi
  • Benaque, Alba
  • Clarimón, Jordi
  • Bullido, María Jesús
  • García-Ribas, Guillermo
  • Pastor, Pau
  • Sánchez-Juan, Pascual
  • Álvarez, Victoria
  • Piñol-Ripoll, Gerard
  • García-Alberca, Jose Maria
  • Royo, José Luis
  • Franco, Emilio
  • Mir, Pablo
  • Calero, Miguel
  • Medina, Miguel
  • Rábano, Alberto
  • Ávila, Jesús
  • Antúnez, Carmen
  • Real, Luis Miguel
  • Orellana, Adelina
  • Carracedo Álvarez, Ángel
  • Saéz, Maria Eugenia
  • Tárraga, Lluís
  • Boada, Mercè
  • Ruiz, Agustín
Introduction: Large variability among Alzheimer's disease (AD) cases might impact genetic discoveries and complicate dissection of underlying biological pathways. Methods: Genome Research at Fundacio ACE (GR@ACE) is a genome-wide study of dementia and its clinical endophenotypes, defined based on AD's clinical certainty and vascular burden. We assessed the impact of known AD loci across endophenotypes to generate loci categories. We incorporated gene coexpression data and conducted pathway analysis per category. Finally, to evaluate the effect of heterogeneity in genetic studies, GR@ACE series were meta-analyzed with additional genome-wide association study data sets. Results: We classified known AD loci into three categories, which might reflect the disease clinical heterogeneity. Vascular processes were only detected as a causal mechanism in probable AD. The meta-analysis strategy revealed the ANKRD31-rs4704171 and NDUFAF6-rs10098778 and confirmed SCIMP-rs7225151 and CD33-rs3865444. Discussion: The regulation of vasculature is a prominent causal component of probable AD. GR@ACE meta-analysis revealed novel AD genetic signals, strongly driven by the presence of clinical heterogeneity in the AD series.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A C6orf10 / LOC101929163 locus is associated with age of onset in C9orf72 carriers

  • Zhang, Ming
  • Ferrari, Raffaele
  • Tartaglia, Maria Carmela
  • Keith, Julia
  • Surace, Ezequiel I.
  • Wolf, Uri
  • Sato, Christine
  • Grinberg, Mark
  • Liang, Yan
  • Xi, Zhengrui
  • Dupont, Kyle
  • McGoldrick, Philip
  • Weichert, Anna
  • McKeever, Paul M.
  • Schneider, Raphael
  • McCorkindale, Michael D.
  • Manzoni, Claudia|||0000-0001-5367-4023
  • Rademakers, Rosa
  • Graff-Radford, Neill R.
  • Dickson, Dennis W.|||0000-0001-7189-7917
  • Parisi, Joseph E.
  • Boeve, Bradley
  • Petersen, Ronald C.
  • Miller, Bruce L.|||0000-0002-2152-4220
  • Seeley, William W.
  • van Swieten, John C.
  • van Rooij, Jeroen
  • Pijnenburg, Yolande|||0000-0003-2464-1905
  • Van der Zee, Julie|||0000-0003-4381-8040
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Le Ber, Isabelle|||0000-0002-2508-5181
  • Van Deerlin, Vivianna|||0000-0002-7400-9097
  • Suh, EunRan
  • Rohrer, Jonathan D.
  • Mead, Simon|||0000-0002-4326-1468
  • Graff, Caroline|||0000-0002-9949-2951
  • Öijerstedt, Linn
  • Pickering-Brown, S.|||0000-0003-1561-6054
  • Rollinson, Sara|||0000-0002-0921-4318
  • Rossi, Giacomina|||0000-0001-6680-2725
  • Tagliavini, Fabrizio|||0000-0003-1039-7315
  • Brooks, William S.
  • Dobson-Stone, Carol
  • Halliday, Glenda M.
  • Hodges, John R.
  • Piguet, Olivier
  • Binetti, Giuliano|||0000-0003-2759-5844
  • Benussi, Luisa|||0000-0003-2836-8141
  • Ghidoni, Roberta|||0000-0002-7691-1957
  • Nacmias, Benedetta|||0000-0001-9338-9040
  • Sorbi, Sandro|||0000-0002-0380-6670
  • Bruni, Amalia|||0000-0003-3471-3343
  • Galimberti, Daniela|||0000-0002-9284-5953
  • Scarpini, Elio|||0000-0002-6395-2119
  • Rainero, Innocenzo|||0000-0001-6074-9628
  • Rubino, Elisa|||0000-0002-7553-7553
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Lleó, Alberto|||0000-0002-2568-5478
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Hernández, Isabel|||0000-0001-8119-393X
  • Pastor, Pau|||0000-0002-7493-8777
  • Diez-Fairen, Monica|||0000-0003-1882-0309
  • Borroni, Barbara|||0000-0001-9340-9814
  • Pasquier, Florence|||0000-0001-9880-9788
  • Deramecourt, Vincent
  • Lebouvier, Thibaud
  • Perneczky, Robert|||0000-0003-1981-7435
  • Diehl-Schmid, Janine|||0000-0002-7745-1382
  • Grafman, Jordan
  • Huey, Edward D.
  • Mayeux, Richard|||0000-0001-6519-9696
  • Nalls, Michael A..
  • Hernandez, Dena
  • Singleton, Andrew B.|||0000-0001-5606-700X
  • Momeni, Parastoo
  • Zeng, Zhen
  • Hardy, John|||0000-0002-3122-0423
  • Robertson, Janice
  • Zinman, Lorne
  • Rogaeva, Ekaterina
Discovery of disease age-of-onset modifiers is important for clinical trials and drug design. Zhang et al. perform a genome-wide analysis of epigenetic functional polymorphisms and identify an association between the C6orf10/LOC101929163 locus and age of FTD/ALS onset. The risk allele may be associated with a pro-inflammatory state in the brain. The GC-repeat expansion in C9orf72 is the most common known cause of amyotrophic lateral sclerosis and frontotemporal dementia. The high phenotypic heterogeneity of C9orf72 patients includes a wide range in age of onset, modifiers of which are largely unknown. Age of onset could be influenced by environmental and genetic factors both of which may trigger DNA methylation changes at CpG sites. We tested the hypothesis that age of onset in C9orf72 patients is associated with some common single nucleotide polymorphisms causing a gain or loss of CpG sites and thus resulting in DNA methylation alterations. Combined analyses of epigenetic and genetic data have the advantage of detecting functional variants with reduced likelihood of false negative results due to excessive correction for multiple testing in genome-wide association studies. First, we estimated the association between age of onset in C9orf72 patients (n = 46) and the DNA methylation levels at all 7603 CpG sites available on the 450 k BeadChip that are mapped to common single nucleotide polymorphisms. This was followed by a genetic association study of the discovery (n = 144) and replication (n = 187) C9orf72 cohorts. We found that age of onset was reproducibly associated with polymorphisms within a 124.7 kb linkage disequilibrium block tagged by top-significant variation, rs9357140, and containing two overlapping genes (LOC101929163 and C6orf10). A meta-analysis of all 331 C9orf72 carriers revealed that every A-allele of rs9357140 reduced hazard by 30% (P = 0.0002); and the median age of onset in AA-carriers was 6 years later than GG-carriers. In addition, we investigated a cohort of C9orf72 negative patients (n = 2634) affected by frontotemporal dementia and/or amyotrophic lateral sclerosis; and also found that the AA-genotype of rs9357140 was associated with a later age of onset (adjusted P = 0.007 for recessive model). Phenotype analyses detected significant association only in the largest subgroup of patients with frontotemporal dementia (n = 2142, adjusted P = 0.01 for recessive model). Gene expression studies of frontal cortex tissues from 25 autopsy cases affected by amyotrophic lateral sclerosis revealed that the G-allele of rs9357140 is associated with increased brain expression of LOC101929163 (a non-coding RNA) and HLA-DRB1 (involved in initiating immune responses), while the A-allele is associated with their reduced expression. Our findings suggest that carriers of the rs9357140 GG-genotype (linked to an earlier age of onset) might be more prone to be in a pro-inflammatory state (e.g. by microglia) than AA-carriers. Further, investigating the functional links within the C6orf10 / LOC101929163 / HLA-DRB1 pathway will be critical to better define age-dependent pathogenesis of frontotemporal dementia and amyotrophic lateral sclerosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts

  • Costa, Beatrice
  • Manzoni, Claudia|||0000-0001-5367-4023
  • Bernal-Quiros, Manuel
  • Kia, Demis A.
  • Aguilar Barberà, Miquel
  • Alvarez, Ignacio|||0000-0002-8537-3935
  • Alvarez, Victoria|||0000-0002-1916-2523
  • Andreassen, Ole A.|||0000-0002-4461-3568
  • Anfossi, Maria
  • Bagnoli, Silvia
  • Benussi, Luisa|||0000-0003-2836-8141
  • Bernardi, Livia
  • Binetti, Giuliano|||0000-0003-2759-5844
  • Blackburn, Daniel
  • Boada, Mercè|||0000-0003-2617-3009
  • Borroni, Barbara|||0000-0001-9340-9814
  • Bowns, Lucy
  • Bråthen, Geir|||0000-0003-3224-7983
  • Bruni, Amalia|||0000-0003-3471-3343
  • Chiang, Huei-Hsin
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Colville, Shuna
  • Conidi, Maria E.
  • Cope, Tom E.
  • Cruchaga, Carlos|||0000-0002-0276-2899
  • Cupidi, Chiara
  • Di Battista, Maria Elena
  • Diehl-Schmid, Janine|||0000-0002-7745-1382
  • Diez-Fairen, Monica|||0000-0003-1882-0309
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Durante, Elisabetta
  • Flisar, Dušan
  • Frangipane, Francesca
  • Galimberti, Daniela|||0000-0002-9284-5953
  • Gallo, Maura
  • Gallucci, Maurizio
  • Ghidoni, Roberta|||0000-0002-7691-1957
  • Graff, Caroline|||0000-0002-9949-2951
  • Grafman, Jordan H.
  • Grossman, Murray|||0000-0002-7447-6218
  • Hardy, John|||0000-0002-3122-0423
  • Hernández, Isabel|||0000-0001-8119-393X
  • Holloway, Guy J. T.
  • Huey, Edward D.
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Karydas, Anna
  • Khoshnood, Behzad
  • Kramberger, Milica G.
  • Kristiansen, Mark
  • Lewis, Patrick|||0000-0003-4537-0489
  • Lleó, Alberto|||0000-0002-2568-5478
  • Madhan, Gaganjit K.
  • Maletta, Raffaele|||0000-0002-0758-1835
  • Maver, Ales
  • Menéndez González, Manuel
  • Milan, Graziella
  • Miller, Bruce L.|||0000-0002-2152-4220
  • Mol, Merel O.|||0000-0003-2533-2530
  • Momeni, Parastoo
  • Moreno-Grau, Sonia
  • Morris, Chris M.|||0000-0002-3749-0993
  • Nacmias, Benedetta|||0000-0001-9338-9040
  • Nilsson, Christer
  • Novelli, Valeria
  • Öijerstedt, Linn
  • Padovani, Alessandro|||0000-0002-0119-3639
  • Pal, Suvankar
  • Panchbhaya, Yasmin
  • Pastor, Pau|||0000-0002-7493-8777
  • Peterlin, Borut|||0000-0001-7824-4978
  • Piaceri, Irene|||0000-0001-6787-2223
  • Pickering-Brown, S.|||0000-0003-1561-6054
  • Pijnenburg, Yolande|||0000-0003-2464-1905
  • Puca, Annibale A.
  • Rainero, Innocenzo|||0000-0001-6074-9628
  • Rendina, Antonella|||0000-0001-5331-2807
  • Richardson, Anna M. T.
  • Rogaeva, Ekaterina
  • Rogelj, Boris|||0000-0003-3898-1943
  • Rollinson, Sara|||0000-0002-0921-4318
  • Rossi, Giacomina|||0000-0001-6680-2725
  • Rossmeier, Carola
  • Rowe, James B.
  • Rubino, Elisa|||0000-0002-7553-7553
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Sando, Sigrid B.
  • Santillo, Alexander F.
  • Saxon, Jennifer
  • Scarpini, Elio|||0000-0002-6395-2119
  • Serpente, Maria
  • Smirne, Nicoletta
  • Sorbi, Sandro|||0000-0002-0380-6670
  • Suh, EunRan
  • Tagliavini, Fabrizio|||0000-0003-1039-7315
  • Thompson, Jennifer C.
  • Trojanowski, John Q.|||0000-0002-9239-8794
  • Van Deerlin, Vivianna|||0000-0002-7400-9097
  • Van der Zee, Julie|||0000-0003-4381-8040
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • van Rooij, Jeroen
  • van Swieten, John C.
  • Veronesi, Arianna
  • Vitale, Emilia|||0000-0003-4651-3875
  • Waldö, Maria L.
  • Woodward, Cathy
  • Yokoyama, Jennifer S.|||0000-0001-7274-2634
  • Escott-Price, Valentina|||0000-0003-1784-5483
  • Polke, James M.
  • Ferrari, Raffaele
We sought to characterize C9orf72 expansions in relation to genetic ancestry and age at onset (AAO) and to use these measures to discriminate the behavioral from the language variant syndrome in a large pan-European cohort of frontotemporal lobar degeneration (FTLD) cases. We evaluated expansions frequency in the entire cohort (n = 1,396; behavioral variant frontotemporal dementia [bvFTD] [n = 800], primary progressive aphasia [PPA] [n = 495], and FTLD-motor neuron disease [MND] [n = 101]). We then focused on the bvFTD and PPA cases and tested for association between expansion status, syndromes, genetic ancestry, and AAO applying statistical tests comprising Fisher exact tests, analysis of variance with Tukey post hoc tests, and logistic and nonlinear mixed-effects model regressions. We found C9orf72 pathogenic expansions in 4% of all cases (56/1,396). Expansion carriers differently distributed across syndromes: 12/101 FTLD-MND (11.9%), 40/800 bvFTD (5%), and 4/495 PPA (0.8%). While addressing population substructure through principal components analysis (PCA), we defined 2 patients groups with Central/Northern (n = 873) and Southern European (n = 523) ancestry. The proportion of expansion carriers was significantly higher in bvFTD compared to PPA (5% vs 0.8% [ p = 2.17 × 10 -5 ; odds ratio (OR) 6.4; confidence interval (CI) 2.31-24.99]), as well as in individuals with Central/Northern European compared to Southern European ancestry (4.4% vs 1.8% [ p = 1.1 × 10 -2 ; OR 2.5; CI 1.17-5.99]). Pathogenic expansions and Central/Northern European ancestry independently and inversely correlated with AAO. Our prediction model (based on expansions status, genetic ancestry, and AAO) predicted a diagnosis of bvFTD with 64% accuracy. Our results indicate correlation between pathogenic C9orf72 expansions, AAO, PCA-based Central/Northern European ancestry, and a diagnosis of bvFTD, implying complex genetic risk architectures differently underpinning the behavioral and language variant syndromes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Neuropsychiatric profiles and conversion to dementia in mild cognitive impairment, a latent class analysis

  • Roberto Herrero, Natalia|||0000-0002-5391-2711
  • Portella Moll, Maria J., 1975-|||0000-0002-2007-9516
  • Marquié, Marta|||0000-0002-0660-0950
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Hernández, Isabel|||0000-0001-8119-393X
  • Mauleón, Ana|||0000-0002-4218-2127
  • Rosende-Roca, Maitée|||0000-0003-1778-8175
  • Abdelnour, Carla|||0000-0002-7636-9758
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Gil-Navarro, Silvia|||0000-0001-9921-9042
  • Tartari, Juan P.
  • Vargas, Liliana|||0000-0001-5685-5903
  • Espinosa, Ana|||0000-0001-7399-3267
  • Ortega Linares, Gemma|||0000-0002-7479-4072
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Sanabria, Ángela|||0000-0002-7501-9895
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Moreno-Grau, Sonia
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Boada, Mercè|||0000-0003-2617-3009
  • Valero, Sergi|||0000-0002-6599-948X
Neuropsychiatric symptoms (NPS) have been recently addressed as risk factors of conversion to Alzheimer's disease (AD) and other dementia types in patients diagnosed with Mild Cognitive Impairment (MCI). Our aim was to determine profiles based on the prominent NPS in MCI patients and to explore the predictive value of these profiles on conversion to specific types of dementia. A total of 2137 MCI patients monitored in a memory clinic were included in the study. Four NPS profiles emerged (classes), which were defined by preeminent symptoms: Irritability, Apathy, Anxiety/Depression and Asymptomatic. Irritability and Apathy were predictors of conversion to dementia (HR = 1.43 and 1.56, respectively). Anxiety/depression class showed no risk effect of conversion when compared to Asymptomatic class. Irritability class appeared as the most discriminant neuropsychiatric condition to identify non-AD converters (i.e., frontotemporal dementia, vascular dementia, Parkinson's disease and dementia with Lewy Bodies). The findings revealed that consistent subgroups of MCI patients could be identified among comorbid basal NPS. The preeminent NPS showed to behave differentially on conversion to dementia, beyond AD. Therefore, NPS should be used as early diagnosis facilitators, and should also guide clinicians to detect patients with different illness trajectories in the progression of MCI.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment

  • Cano, Amanda|||0000-0001-9567-4283
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Bernuz, Mireia|||0000-0002-2052-6902
  • Puerta, Raquel|||0000-0002-1191-5893
  • García-González, Pablo|||0000-0003-0125-5403
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Olivé Roig, Clàudia|||0000-0002-9438-5639
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Núñez-Llaves, Raúl|||0000-0002-6702-4774
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Valero, Sergi|||0000-0002-6599-948X
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Martín, Elvira
  • Martino-Adami, Pamela V.
  • Ettcheto, Miren|||0000-0002-4301-7297
  • Camins, Antoni|||0000-0002-1229-5956
  • Vivas, Assumpta
  • Gómez Chiari, Marta|||0000-0001-6726-1721
  • Tejero, Miguel Ángel
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Marquié, Marta|||0000-0002-0660-0950
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
In the clinical course of Alzheimer's disease (AD) development, the dementia phase is commonly preceded by a prodromal AD phase, which is mainly characterized by reaching the highest levels of Aβ and p-tau-mediated neuronal injury and a mild cognitive impairment (MCI) clinical status. Because of that, most AD cases are diagnosed when neuronal damage is already established and irreversible. Therefore, a differential diagnosis of MCI causes in these prodromal stages is one of the greatest challenges for clinicians. Blood biomarkers are emerging as desirable tools for pre-screening purposes, but the current results are still being analyzed and much more data is needed to be implemented in clinical practice. Because of that, plasma extracellular vesicles (pEVs) are gaining popularity as a new source of biomarkers for the early stages of AD development. To identify an exosome proteomics signature linked to prodromal AD, we performed a cross-sectional study in a cohort of early-onset MCI (EOMCI) patients in which 184 biomarkers were measured in pEVs, cerebrospinal fluid (CSF), and plasma samples using multiplex PEA technology of Olink© proteomics. The obtained results showed that proteins measured in pEVs from EOMCI patients with established amyloidosis correlated with CSF p-tau181 levels, brain ventricle volume changes, brain hyperintensities, and MMSE scores. In addition, the correlations of pEVs proteins with different parameters distinguished between EOMCI Aβ( +) and Aβ(-) patients, whereas the CSF or plasma proteome did not. In conclusion, our findings suggest that pEVs may be able to provide information regarding the initial amyloidotic changes of AD. Circulating exosomes may acquire a pathological protein signature of AD before raw plasma, becoming potential biomarkers for identifying subjects at the earliest stages of AD development.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers

  • Jansen, Iris E.|||0000-0003-1901-8131
  • van der Lee, Sven J.|||0000-0003-1606-8643
  • Gomez-Fonseca, Duber
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Dalmasso, Maria Carolina|||0000-0002-4901-9955
  • Grenier-Boley, Benjamin
  • Zettergren, Anna|||0000-0002-7182-8417
  • Mishra, Aniket|||0000-0002-8141-1543
  • Ali, Muhammad|||0000-0002-1399-6631
  • Andrade, Victor|||0000-0003-0682-269X
  • Bellenguez, Céline|||0000-0002-1240-7874
  • Kleineidam, Luca
  • Küçükali, Fahri
  • Sung, Ju Sung
  • Tesí, Niccolo
  • Vromen, Ellen|||0000-0001-7774-5500
  • Wightman, Douglas P.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Alvarez, Ignacio|||0000-0002-8537-3935
  • Amouyel, Philippe|||0000-0001-9088-234X
  • Athanasiu, Lavinia
  • Bahrami, Shahram
  • Bailly, Henri
  • Belbin, Olivia|||0000-0002-6109-6371
  • Bergh, Sverre|||0000-0001-9593-2967
  • Bertram, Lars|||0000-0002-0108-124X
  • Biessels, Geert Jan|||0000-0001-6862-2496
  • Blennow, Kaj|||0000-0002-1890-4193
  • Blesa, Rafael|||0000-0003-4026-2884
  • Boada, Mercè|||0000-0003-2617-3009
  • Boland, Anne|||0000-0001-8789-5676
  • Buerger, K.
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Cervera Carles, Laura|||0000-0003-2286-200X
  • Chene, Geneviève|||0000-0002-8368-6460
  • Claassen, Jurgen|||0000-0002-1778-8151
  • Debette, Stéphanie|||0000-0001-8675-7968
  • Deleuze, Jean-Francois
  • De Deyn, Peter Paul|||0000-0002-2228-2964
  • Diehl-Schmid, Janine|||0000-0002-7745-1382
  • Djurovic, Srdjan|||0000-0002-8140-8061
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Dufouil, Carole|||0000-0003-2442-4476
  • Duron, Emmanuelle
  • Düzel, Emrah
  • Fladby, Tormod|||0000-0002-9984-9797
  • Fortea, Juan|||0000-0002-1340-638X
  • Froelich, Lutz|||0000-0003-1494-0813
  • García-González, Pablo|||0000-0003-0125-5403
  • Garcia-Martinez, María
  • Giegling, Ina
  • Goldhardt, Oliver
  • Gobom, Johan|||0000-0001-6193-6193
  • Grimmer, Timo
  • Haapasalo, Annakaisa|||0000-0003-0959-2957
  • Hampel, Harald
  • Hanon, Olivier|||0000-0002-4697-122X
  • Hausner, Lucrezia|||0000-0001-9009-2356
  • Heilmann-Heimbach, Stefanie|||0000-0003-1057-465X
  • Helisalmi, Seppo
  • Heneka, Michael|||0000-0003-4996-1630
  • Hernández, Isabel|||0000-0001-8119-393X
  • Herukka, Sanna-Kaisa|||0000-0003-3308-8662
  • Holstege, Henne|||0000-0002-7688-3087
  • Jarholm, Jonas
  • Kern, Silke
  • Knapskog, Anne-Brita
  • Koivisto, A.M.
  • Kornhuber, Johannes|||0000-0002-8096-3987
  • Kuulasmaa, Teemu|||0000-0002-1795-7314
  • Lage, Carmen|||0000-0003-1703-121X
  • Laske, Christoph
  • Leinonen, Ville|||0000-0002-4282-4687
  • Lewczuk, Piotr|||0000-0002-8101-6535
  • Lleó, Alberto|||0000-0002-2568-5478
  • Lopez de Munain, Adolfo|||0000-0002-9509-4032
  • López-Garcia, Sara
  • Maier, Wolfgang
  • Marquié, Marta|||0000-0002-0660-0950
  • Mol, Merel O.|||0000-0003-2533-2530
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Moreno, Fermin|||0000-0001-5200-3164
  • Moreno-Grau, Sonia
  • Nicolas, Gael|||0000-0001-9391-7800
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Pålhaugen, Lene
  • Papma, Janne M.
  • Pasquier, Florence|||0000-0001-9880-9788
  • Perneczky, Robert|||0000-0003-1981-7435
  • Peters, Oliver|||0000-0003-0568-2998
  • Pijnenburg, Yolande A.L.
  • Popp, Julius|||0000-0002-0068-0312
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Pozueta, Ana
  • Priller, Josef|||0000-0001-7596-0979
  • Puerta, Raquel|||0000-0002-1191-5893
  • Quintela, Inés|||0000-0002-0239-7975
  • Ramakers, Inez
  • Rodríguez-Rodríguez, Eloy|||0000-0001-7742-677X
  • Rujescu, Dan|||0000-0002-1432-313X
  • Saltvedt, Ingvild|||0000-0002-7897-9808
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Scheltens, Philip|||0000-0002-1046-6408
  • Scherbaum, Norbert|||0000-0003-1759-6990
  • Schmid, Matthias
  • Schneider, Anja|||0000-0001-9540-8700
  • Selbæk, Geir|||0000-0001-6511-8219
  • Selnes, Per
  • Shadrin, Alexey
  • Skoog, Ingmar
  • Soininen, Hilkka|||0000-0002-2785-9937
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Teipel, Stefan
  • Tijms, Betty M.|||0000-0002-2612-1797
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Van Dongen, Jasper|||0000-0001-5599-0046
  • van Swieten, John C.
  • Vandenberghe, Rik|||0000-0001-6237-2502
  • Vidal, Jean-Sébastien|||0000-0001-6770-0720
  • Visser, Pieter Jelle|||0000-0001-8008-9727
  • Vogelgsang, Jonathan|||0000-0001-9326-8193
  • Waern, Margda|||0000-0002-8330-6915
  • Wagner, Michael
  • Wiltfang, Jens W.
  • Wittens, Mandy M.J.
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Zulaica, Miren
  • van Duijn, Cornelia M.|||0000-0002-2374-9204
  • Bjerke, Maria
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Jessen, Frank
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Pastor, Pau|||0000-0002-7493-8777
  • Hiltunen, Mikko|||0000-0003-3566-4096
  • Ingelsson, Martin|||0000-0001-5466-8370
  • Andreassen, Ole A.|||0000-0002-4461-3568
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Sleegers, Kristel|||0000-0002-0283-2332
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Cruchaga, Carlos|||0000-0002-0276-2899
  • Lambert, Jean-Charles|||0000-0003-0829-7817
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer's disease (AD) more directly than clinical diagnosis. Initiated by the European Alzheimer & Dementia Biobank (EADB), the largest collaborative effort on genetics underlying CSF biomarkers was established, including 31 cohorts with a total of 13,116 individuals (discovery n = 8074; replication n = 5042 individuals). Besides the APOE locus, novel associations with two other well-established AD risk loci were observed; CR1 was shown a locus for Aβ42 and BIN1 for pTau. GMNC and C16orf95 were further identified as loci for pTau, of which the latter is novel. Clustering methods exploring the influence of all known AD risk loci on the CSF protein levels, revealed 4 biological categories suggesting multiple Aβ42 and pTau related biological pathways involved in the etiology of AD. In functional follow-up analyses, GMNC and C16orf95 both associated with lateral ventricular volume, implying an overlap in genetic etiology for tau levels and brain ventricular volume.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characteristics of subjective cognitive decline associated with amyloid positivity

  • Janssen, Olin|||0000-0002-8341-0958
  • Jansen, Willemijn J.
  • Vos, Stephanie J.B.|||0000-0002-2045-9818
  • Boada, Mercè|||0000-0003-2617-3009
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Gabryelewicz, Tomasz
  • Fladby, Tormod|||0000-0002-9984-9797
  • Molinuevo, José Luis|||0000-0003-0485-6001
  • Villeneuve, Sylvia
  • Hort, Jakub|||0000-0002-1080-3726
  • Epelbaum, Stéphane
  • Lleó, Alberto|||0000-0002-2568-5478
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Landau, Susan
  • Popp, Julius|||0000-0002-0068-0312
  • Wallin, Anders|||0000-0001-9506-0513
  • Scheltens, Philip|||0000-0002-1046-6408
  • Rikkert, Marcel Olde|||0000-0003-1397-1677
  • Snyder, Peter J.|||0000-0003-0555-4654
  • Rowe, Chris
  • Chételat, G.|||0000-0002-4889-7932
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Marquié, Marta|||0000-0002-0660-0950
  • Chipi, Elena
  • Wolfsgruber, Steffen
  • Heneka, Michael|||0000-0003-4996-1630
  • Boecker, Henning|||0000-0003-2346-0598
  • Peters, Oliver|||0000-0003-0568-2998
  • Jarholm, Jonas
  • Rami Gonzalez, Lorena|||0000-0002-7411-1921
  • Tort-Merino, Adrià|||0000-0002-5646-0482
  • Pichet Binette, Alexa|||0000-0001-5218-3337
  • Poirier, Judes
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Cerman, Jiri
  • Dubois, Bruno
  • Teichmann, Marc
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Ebenau, Jarith
  • Pocnet, Cornelia
  • Eckerström, Marie
  • Thompson, Louisa
  • Villemagne, Victor
  • Buckley, Rachel|||0000-0002-5356-5537
  • Burnham, Samantha
  • Delarue, Marion
  • Freund-Levi, Yvonne|||0000-0001-6863-6679
  • Wallin, Åsa K.
  • Ramakers, Inez
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Soininen, Hilkka|||0000-0002-2785-9937
  • Hampel, Harald
  • Spiru, Luiza
  • Tijms, Betty M.|||0000-0002-2612-1797
  • Ossenkoppele, Rik
  • Verhey, Frans
  • Jessen, Frank
  • Visser, Pieter Jelle|||0000-0001-8008-9727
Introduction: The evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited. Methods: In 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD-specific characteristics (informant confirmation, domain-specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene (APOE) ε4 carriership, and neuropsychiatric symptoms with amyloid positivity. Results: Between cohorts, amyloid positivity in 70-year-olds varied from 10% to 76%. Only older age, clinical setting, and APOE ε4 carriership showed univariate associations with increased amyloid positivity. After adjusting for these, lower education was also associated with increased amyloid positivity. Only within a research setting, informant-confirmed complaints, memory complaints, attention/concentration complaints, and no depressive symptoms were associated with increased amyloid positivity. Feelings of worse performance were associated with less amyloid positivity at younger ages and more at older ages. Discussion: Next to age, setting, and APOE ε4 carriership, SCD-specific characteristics may facilitate the identification of amyloid-positive individuals.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort

  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • García-González, Pablo|||0000-0003-0125-5403
  • Valero, Sergi|||0000-0002-6599-948X
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Hernández, Isabel|||0000-0001-8119-393X
  • Rosende-Roca, Maitée|||0000-0003-1778-8175
  • Vargas, Liliana|||0000-0001-5685-5903
  • Tartari, Juan Pablo
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Bojaryn, Urszula
  • Narvaiza, Leire
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Pytel, Vanesa
  • Cano, Amanda|||0000-0001-9567-4283
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
Background: Clinical diagnosis of Alzheimer's disease (AD) increasingly incorporates CSF biomarkers. However, due to the intrinsic variability of the immunodetection techniques used to measure these biomarkers, establishing in-house cutoffs defining the positivity/negativity of CSF biomarkers is recommended. However, the cutoffs currently published are usually reported by using cross-sectional datasets, not providing evidence about its intrinsic prognostic value when applied to real-world memory clinic cases. Methods: We quantified CSF Aβ1-42, Aβ1-40, t-Tau, and p181Tau with standard INNOTEST® ELISA and Lumipulse G® chemiluminescence enzyme immunoassay (CLEIA) performed on the automated Lumipulse G600II. Determination of cutoffs included patients clinically diagnosed with probable Alzheimer's disease (AD, n = 37) and subjective cognitive decline subjects (SCD, n = 45), cognitively stable for 3 years and with no evidence of brain amyloidosis in 18F-Florbetaben-labeled positron emission tomography (FBB-PET). To compare both methods, a subset of samples for Aβ1-42 (n = 519), t-Tau (n = 399), p181Tau (n = 77), and Aβ1-40 (n = 44) was analyzed. Kappa agreement of single biomarkers and Aβ1-42/Aβ1-40 was evaluated in an independent group of mild cognitive impairment (MCI) and dementia patients (n = 68). Next, established cutoffs were applied to a large real-world cohort of MCI subjects with follow-up data available (n = 647). Results: Cutoff values of Aβ1-42 and t-Tau were higher for CLEIA than for ELISA and similar for p181Tau. Spearman coefficients ranged between 0.81 for Aβ1-40 and 0.96 for p181TAU. Passing-Bablok analysis showed a systematic and proportional difference for all biomarkers but only systematic for Aβ1-40. Bland-Altman analysis showed an average difference between methods in favor of CLEIA. Kappa agreement for single biomarkers was good but lower for the Aβ1-42/Aβ1-40 ratio. Using the calculated cutoffs, we were able to stratify MCI subjects into four AT(N) categories. Kaplan-Meier analyses of AT(N) categories demonstrated gradual and differential dementia conversion rates (p = 9.815). Multivariate Cox proportional hazard models corroborated these findings, demonstrating that the proposed AT(N) classifier has prognostic value. AT(N) categories are only modestly influenced by other known factors associated with disease progression. Conclusions: We established CLEIA and ELISA internal cutoffs to discriminate AD patients from amyloid-negative SCD individuals. The results obtained by both methods are not interchangeable but show good agreement. CLEIA is a good and faster alternative to manual ELISA for providing AT(N) classification of our patients. AT(N) categories have an impact on disease progression. AT(N) classifiers increase the certainty of the MCI prognosis, which can be instrumental in managing real-world MCI subjects.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer's disease

  • Wang, Lihua
  • Nykänen, Niko-Petteri
  • Western, Daniel|||0000-0003-3725-9553
  • Gorijala, Priyanka
  • Timsina, Jigyasha
  • Li, Fuhai
  • Wang, Zhaohua
  • Ali, Muhammad|||0000-0002-1399-6631
  • Yang, Chengran
  • Liu, Menghan
  • Brock, William
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
  • Alvarez, Ignacio|||0000-0002-8537-3935
  • Aguilar, Miquel
  • Pastor, Pau|||0000-0002-7493-8777
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Puerta, Raquel|||0000-0002-1191-5893
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Rutledge, Jarod
  • Oh, Hamilton
  • Greicius, Michael. D.
  • Le Guen, Yann Le
  • Perrin, Richard J.
  • Wyss-Coray, Tony
  • Jefferson, Angela
  • Hohman, Timothy J.
  • Graff-Radford, Neill
  • Mori, Hiroshi
  • Goate, Alison|||0000-0002-0576-2472
  • Levin, Johannes|||0000-0001-5092-4306
  • Sung, Yun Ju
  • Cruchaga, Carlos|||0000-0002-0276-2899
Triggering receptor expressed on myeloid cells 2 (TREM2) plays a critical role in microglial activation, survival, and apoptosis, as well as in Alzheimer's disease (AD) pathogenesis. We previously reported the MS4A locus as a key modulator for soluble TREM2 (sTREM2) in cerebrospinal fluid (CSF). To identify additional novel genetic modifiers of sTREM2, we performed the largest genome-wide association study (GWAS) and identified four loci for CSF sTREM2 in 3,350 individuals of European ancestry. Through multi-ethnic fine mapping, we identified two independent missense variants (p.M178V in MS4A4A and p.A112T in MS4A6A) that drive the association in MS4A locus and showed an epistatic effect for sTREM2 levels and AD risk. The novel TREM2 locus on chr 6 contains two rare missense variants (rs75932628 p.R47H, P=7.16×10; rs142232675 p.D87N, P=2.71×10) associated with sTREM2 and AD risk. The third novel locus in the TGFBR2 and RBMS3 gene region (rs73823326, P=3.86×10) included a regulatory variant with a microglia-specific chromatin loop for the promoter of TGFBR2. Using cell-based assays we demonstrate that overexpression and knock-down of TGFBR2, but not RBMS3, leads to significant changes of sTREM2. The last novel locus is located on the APOE region (rs11666329, P=2.52×10), but we demonstrated that this signal was independent of APOE genotype. This signal colocalized with cis-eQTL of NECTIN2 in the brain cortex and cis-pQTL of NECTIN2 in CSF. Overexpression of NECTIN2 led to an increase of sTREM2 supporting the genetic findings. To our knowledge, this is the largest study to date aimed at identifying genetic modifiers of CSF sTREM2. This study provided novel insights into the MS4A and TREM2 loci, two well-known AD risk genes, and identified TGFBR2 and NECTIN2 as additional modulators involved in TREM2 biology.